CLSI and the Canadian Technology Accelerator Program Partner Again to Assist Emerging Canadian Life Science Companies
For the second year in a row, the California Life Sciences Institute (CLSI) is partnering with the Canadian Technology Accelerator (CTA) San Francisco – Life Sciences to deliver a 16-week winter program that will provide five Canadian early-stage companies with customized mentorship and in-market programming to advance their commercialization strategies. The San Francisco In Market Program will kick off next month, with the Canadian companies joining CLSI’s FAST Bay Area companies at a second FAST International Showcase on December 10.
The Canadian Technology Accelerator-Life Sciences (CTA-LS) San Francisco is an intensive program run by the Consulate General of Canada in San Francisco, which offers high-potential Canadian companies – in biopharmaceuticals, digital health, medical devices, imaging, precision medicine/genetics, research tools, and diagnostics – strategic guidance and tailored resources to help expand their business in a global hub for the life sciences sector. CLSI was selected to help deliver the 2019 San Francisco CTA-LS program.
The five Canadian companies are:
AntoXa Corporation – developing an antibody against ricin
Avro – developing a platform transdermal technology for the passive delivery of small molecules
Cohesys – developing a platform of surgical adhesives
Neuraura – developing neuromodulation implants to map the brain and ultimately improve the lives of patients suffering from neurological diseases
NURO – developing a brain-computer interface that allows highly incapacitated individuals with akinetic mutism to communicate using live bio-neurological signals
The Canadian partnership falls under CLSI’s FAST International program for non-US based life science clusters. FAST International is intended to help foreign partners grow their regional economies by helping their life science startups gain commercial footholds in US markets, while enabling these startups to develop subsidiaries or commercial spin-offs in U.S. markets. For more information, contact email@example.com.